Vyvanse® Chewable Tablet added to Ontario Formulary
Vyvanse® (lisdexamfetamine dimesylate) chewable tablet will be publically reimbursed in Ontario for ADHD treatment from March 31, 2020 for patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Vyvanse® chewable tablets are administered once daily in the morning and are available in six doses: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg.
To learn more about the eligibility criteria for reimbursement of Vyvanse® (lisdexamfetamine dimesylate) chewable tablet in Ontario, please visit: